Pfizer Stock Price (NYSE:PFE) Trades at $25.30 With 6.80% Dividend Yield After Q1 Revenue Beats by $649M

Pfizer Inc. (NYSE:PFE) is trading at $25.30 in the Monday session, fractionally below the $25.33 prior close, with an intraday range running between $25.20 and $25.39. The 52-week trading band sits at $22.64 to $28.75, which means the current price is roughly 11.6% above the year low and 12% below the year high — squarely in the middle of a multi-quarter consolidation that has frustrated holders for the better part of 18 months. Market capitalization stands at $144.08 billion. Average daily volume is heavy at 35.48 million shares. The P/E ratio prints 19.33 on a trailing basis, but the more important figure for valuation purposes is the non-GAAP forward P/E, which spans 8.55x to 9.1x depending on which sell-side desk is doing the math. The dividend yield is now an eye-catching 6.80%, which is roughly 319% above the healthcare sector median yield of 1.56%. (Real-time chart and order book: https://www.tradingnews.com/Stocks/PFE/real_time_chart.)

The question that matters for anyone sizing this name is whether the operational improvement showing up in Q1 prints, the Seagen-led acquired-products engine, the Vyndamax exclusivity extension, and the $7.2 billion cost-out plan are sufficient to break the stock out of the range that has trapped it since the COVID hangover began. The answer requires unpacking each piece of the mosaic against the patent cliff, the leveraged balance sheet, and the negative EPS revision trajectory the Street is still working with.

Q1 2026 Print: A Topline Beat Built on Acquired Assets

The headline numbers were genuinely strong. Pfizer (PFE) delivered $14.45 billion in Q1 revenue, up 5.37% year-over-year on the Google Finance read and roughly 5.7% on the company's own framing. That beat consensus estimates by $649 million. Diluted EPS came in at $0.75, exceeding consensus by $0.03 and marking the twelfth consecutive quarterly EPS beat. Net income was $2.69 billion, down 9.44% year-on-year, with the net profit margin compressing to 18.59% from the prior year's comparison.

Operating expenses rose 2.78% year-over-year to $6.48 billion, well below the topline growth rate, which is the structural signature of operating leverage finally working. EBITDA printed $6.18 billion, off 4.01% year-on-year, reflecting the continued drag from declining COVID-related revenue. The effective tax rate at 14.55% remains favorable relative to peers.

The profitability profile is the part of this story that the market has been chronically undervaluing. Operating margin sits at 38%. EBITDA margin is 40.21%, which compares to a sector median of just 10.45% — Pfizer's EBITDA margin is roughly four times the broader pharmaceutical sector. Gross margin is 74.8% against a sector median of 59.58%. These are franchise-level profitability metrics, and they are not what a stock trading at 8.55x to 9.1x forward earnings is supposed to look like in a normalized environment.

The Acquired-Products Engine Is the Single Most Important Variable

The launched and acquired products segment generated $3.1 billion in Q1 revenue with 22% operational growth year-over-year. Extrapolating that quarterly figure produces an annual run rate north of $12 billion. The 22% growth rate compares to Pfizer's overall 2% operational growth across the legacy book, which means the acquired portfolio is mechanically becoming a larger share of total revenue every quarter. As that share grows, the corporate-level revenue growth trajectory mathematically accelerates.

The drug-by-drug performance within the acquired and launch portfolio tells the story. Eliquis revenue hit $2.17 billion in Q1, up 13% year-over-year, beating estimates of $1.93 billion by a wide margin. Nurtec volume expanded 41%. Oncology assets integrated from the $43 billion Seagen acquisition delivered 20% operational growth year-over-year. Lorbrena, the ALK/ROS1 TKI used in advanced non-small cell lung cancer, posted $305 million in Q1 — up 37.4% year-on-year and 8.2% quarter-on-quarter. Padcev, the anti-Nectin-4 antibody-drug conjugate, delivered $591 million in the quarter, climbing 16.3% sequentially and 38.7% year-over-year.

This is the offset to the patent cliff. The question is whether the offset is durable and large enough.

The Vyndamax Settlement Just Reframed the Entire Patent Cliff Math

The single most underappreciated catalyst for NYSE:PFE in Q1 was the Vyndamax patent settlement announced April 28. Pfizer reached agreements with Hikma Pharmaceuticals, Dexcel Pharma, and Cipla that delay U.S. generic entry for the tafamidis franchise until June 1, 2031. Vyndamax derives more than $6 billion in annual revenue and is the leader in the ATTR-CM treatment market. Q1 tafamidis sales were approximately $1.6 billion, up 7.8% year-on-year, holding share even against competition from BridgeBio's Attruby and Alnylam's Amvuttra.

The math here matters. CEO Albert Bourla had previously guided to roughly $17 billion in topline exposure from loss-of-exclusivity events before FY30. The Vyndamax settlement reduces that exposure to roughly $14 billion to $15 billion. That is a $2 billion to $3 billion reduction in the cumulative patent cliff hit, achieved through litigation strategy rather than R&D output. For a company carrying $64.73 billion in total debt, that extension provides meaningful additional cash flow visibility through the back half of the decade — and it pushes the LOE pressure deeper into a period where the obesity portfolio, Padcev expansion, and other oncology assets should be hitting their stride.

Padcev Is the Long-Term Oncology Growth Engine

Within the oncology segment, which generated $3.826 billion in Q1, Padcev is the clearest growth story. The 38.7% year-over-year growth was driven by accelerating demand following its November 21, 2025 FDA approval in combination with Merck's Keytruda for muscle-invasive bladder cancer in patients ineligible for cisplatin. Bladder cancer has a global addressable market of roughly 614,000 patients annually.

The bigger catalyst is approaching. On April 20, the FDA accepted Pfizer's supplemental Biologics License Application for Priority Review covering Padcev plus Keytruda or Keytruda Qlex as treatment for MIBC patients regardless of cisplatin eligibility. The PDUFA date implies approval by August 17. The underlying Phase 3 EV-304 data showed a 47% reduction in the risk of death, disease progression, or tumor recurrence versus the standard-of-care gemcitabine and cisplatin regimen, with the primary endpoint achieved at P<0.0001. A 50% expansion in Padcev's eligible patient population would represent a step-change in the oncology revenue trajectory.

Beyond Padcev, the Elrexfio (elranatamab) Phase 3 MagnetisMM-5 trial demonstrated improved progression-free survival versus the daratumumab/dexamethasone/pomalidomide combination in relapsed/refractory multiple myeloma patients with at least one prior line of therapy. Multiple myeloma globally affects 187,000 patients per year. Specific PFS, ORR, and CR figures have not been disclosed yet, which limits comparative analysis against Tecvayli, Talvey, Sarclisa, and the J&J/Legend CAR-T Carvykti. The ASCO 2026 meeting from May 29 to June 2 will be the venue for granular disclosure across more than 40 abstracts Pfizer is presenting.

Lorbrena, Talzenna, and ASCO 2026: The Oncology Catalysts Stack

Pfizer's ASCO presentation slate includes Lorbrena, Talzenna paired with Xtandi, Tukysa, and experimental candidates including PF-4404 and sigvotatug vedotin. The most-anticipated readout is the 7-year follow-up from the Phase 3 CROWN trial of Lorbrena in ALK-positive non-small cell lung cancer. The CROWN data has been one of the strongest oncology readouts in recent memory, and a confirmation of durable response at the 7-year mark would meaningfully expand Lorbrena's commercial trajectory.

The atirmociclib Phase 2 FOURLIGHT-1 study positions Pfizer's Ibrance successor for a meaningful second wave of CDK inhibitor revenue as Ibrance itself faces eventual generic erosion. The pipeline depth across breast, thoracic, gastrointestinal, and hematologic malignancies provides the multi-year R&D output that can sustain the single-digit topline CAGR Pfizer is projecting from FY29 forward.

The industry context here is unambiguously positive. Global anti-cancer drug spending is projected to grow from $223 billion in 2023 to $409 billion by 2028 — a 45.5% expansion over five years. Pfizer's oncology franchise is positioned to capture a disproportionate share of that growth given the Seagen integration, the Padcev label expansions, and the pipeline depth.

The Adcetris Soft Spot and Segment Reorganization

The risk inside the oncology segment is Adcetris, the CD30 antibody-drug conjugate used in various lymphoma indications. Q1 Adcetris sales were $190 million, down 13.6% sequentially and 12.8% year-over-year. That decline reflects competitive pressure across lymphoma treatment, and the trajectory needs to stabilize for the broader oncology growth story to fully play out. Pfizer also reorganized segment reporting in Q1, moving biosimilars and off-patent branded products like Sulperazon and Zithromax from Specialty Care into a new Hospital and Biosimilars portfolio. That new segment generated $1.85 billion in Q1, up 13.1% year-over-year — a clean double-digit growth contributor that had previously been buried in the Specialty Care reporting line.

Specialty Care itself delivered $2.939 billion in Q1, up 12.3% year-on-year. Combined with the Hospital and Biosimilars growth and the Oncology segment performance, three of Pfizer's four major operating units are now generating double-digit operational growth. The exception, and it is a meaningful one, is Primary Care.

Primary Care: The Drag That Keeps Compressing the Multiple

The Primary Care segment delivered $5.542 billion in Q1, contracting 30.1% sequentially and 2.6% year-over-year. The driver of that compression is the rapid run-off of COVID-related products. Paxlovid revenue fell 62% year-over-year to just $186 million, missing consensus estimates of $248.4 million. Comirnaty sales also contracted sharply, with management citing the absence of the U.K. contract in FY26 and standard seasonality factors. Combined, Paxlovid and Comirnaty accounted for only 1.6% of total Q1 revenue, a dramatic step down from the peak pandemic contribution.

The Primary Care contraction is the single biggest reason PFE trades at a sub-9x forward earnings multiple while peers like Eli Lilly and Novo Nordisk trade at growth-stock multiples. The market is mechanically extending the COVID run-off pattern across the rest of the portfolio, even though the acquired and launched assets are growing at 22% and the broader pharmaceutical franchise excluding COVID is back to mid-single-digit growth.

The Cost-Cutting Program Is the Underappreciated Lever

Pfizer is targeting $7.2 billion in net cost savings before the end of FY26. The company already realized $175 million in manufacturing optimization savings during Q1, which is a small but directionally encouraging tracking number against the broader target. The math on this is straightforward — removing $7.2 billion in costs lowers the breakeven point dramatically and creates earnings leverage as the acquired growth assets continue to expand. R&D expenses did rise 11% operationally in Q1, reflecting the increased investment in the 10 Phase 3 programs being initiated this year, but that R&D increase is happening alongside structural cost-out in other operating lines.

A 38% operating margin on a $14.45 billion quarterly revenue base, scaled to a $58 billion annual run rate and supplemented by $7.2 billion in additional cost reductions, generates a powerful earnings recovery curve. The question is whether the gross margin pressure from rising royalty expenses on acquired assets — which Q1 results showed accruing meaningfully — offsets enough of that operating leverage to compress the net upside.

The Debt Load Is the Single Biggest Risk to the Thesis

Pfizer carries $64.73 billion in total debt against $13.08 billion in cash and short-term investments — the latter figure down 24.47% year-over-year, which is the troubling part. The leverage ratio ended Q1 at 2.8x, and management has guided to leverage remaining at this level or higher through the transition period. Servicing $64.73 billion in debt against a free cash flow base that is currently under pressure — Q1 free cash flow was just $418.13 million, down 71.59% year-on-year — is the single biggest pressure point on the balance sheet.

Levered FCF growth year-on-year is running at minus 14.95%, and operating cash flow growth year-over-year is minus 14.33%. Those negative growth rates compounded against the absolute debt level create a real tension. Pfizer is also funding additional licensing deals, including a $30 million payment to Novavax during Q1 for use of the Matrix-M adjuvant. Royalty expenses on partnered and acquired assets are rising structurally as the revenue mix continues to shift toward acquired products.

The good news is that cash from operations actually rose 11.99% year-over-year to $2.62 billion in Q1, which suggests the operational engine is producing real cash even as headline FCF is being squeezed by capital allocation choices. The Q1 net change in cash was a positive $563 million, up 50.53% year-over-year. The cash flow picture is more nuanced than the FCF number alone implies.

The Earnings Revision Trajectory Is the Most Bearish Single Datapoint

The element of the NYSE:PFE thesis that hardcore value-oriented capital cannot fully wave away is the consensus EPS revision trajectory. The current consensus EPS growth rate for December 2026 sits at minus 7.86%. For December 2027, it is minus 4.12%. For December 2028, it deteriorates to minus 14.94%. For December 2029, it is minus 8.1%. The forward long-term 3-5 year EPS CAGR is minus 2.52%.

These are bear-market-grade revision numbers. The Street is not pricing in a recovery. The Street is pricing in continued deterioration. That is precisely why the stock trades at 8.55x to 9.1x forward earnings while the broader healthcare sector trades at 16.71x to 16.9x. If those consensus EPS estimates prove too pessimistic — and the Q1 EPS beat suggests they might be — the multiple expansion alone produces meaningful upside even without raising the absolute earnings estimates. A move from 9x to 12x forward earnings on flat earnings would deliver roughly 33% price appreciation. That is the math underlying every Strong Buy and Buy rating on the stock from the long-side analyst community.

Weight Loss: The Optionality Nobody Is Pricing

The element of the Pfizer thesis that gets the least credit in the current valuation is the weight loss pipeline. Pfizer has 10 Phase 3 obesity programs ready to initiate this year. The Metsera acquisition provides the platform for ultra-long-acting peptides, with a first approval targeted for FY28. PF-08653944 (formerly MET-097i) is already enrolling patients in two Phase 3 trials — NCT07400653 in patients with obesity and type 2 diabetes, and NCT07311850 in obese patients with weight-related comorbidities excluding T2D.

The China optionality is meaningful. Pfizer's partnership with Hangzhou Sciwind Biosciences gives the company exposure to one of the fastest-growing weight loss markets globally. The Chinese obesity treatment market is structurally large and underpenetrated, and Pfizer entering with a partnered approach allows it to capture revenue without the full cost of building distribution from scratch.

Pfizer currently has zero meaningful revenue from GLP-1 or related obesity therapies. The competitive landscape is dominated by Novo Nordisk and Eli Lilly, and Pfizer is unlikely to displace either at the top of the market. But even capturing 5% to 10% of the obesity treatment market by the early 2030s would represent a multi-billion-dollar revenue stream that is not in current consensus estimates. That is real optionality, and at 8.55x forward earnings, the investor is being paid to wait for it.

FDA Leadership Turbulence Has Not Hurt Pfizer

The FDA leadership shake-up over the past two weeks has been dramatic. Marty Makary resigned as FDA Commissioner on May 12. Tracy Beth Høeg was fired as Director of CDER on May 15. RFK Jr.'s controversial positions on ivermectin, SSRIs, and vaccines have continued to undermine perceived agency independence. None of this has materially affected PFE because Comirnaty accounts for only 1.6% of revenue and the broader pipeline is moving forward through existing regulatory frameworks.

Notably, the reforms instituted under Makary — drug review timelines compressed from one year to two-to-three months — have not been reversed. The National Priority Voucher pilot program, which accelerated approvals for Novo Nordisk's 7.2 mg Wegovy formulation and J&J's Tecvayli plus Darzalex Faspro combination, remains in place. The faster review timelines are structurally positive for Pfizer's pipeline cadence, particularly for the Padcev plus Keytruda label expansion expected by August 17 and the obesity drug pipeline scheduled for first approval in FY28.